PriceTargets.com logo

MDxHealth - MDXH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 177.78%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.88 As of 09/28/2023 03:11 PM ET
▲ +0.08 (2.86%)

This chart shows the closing price for MDXH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MDxHealth Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDXH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDXH

Analyst Price Target is $8.00
▲ +177.78% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MDxHealth in the last 3 months. The average price target is $8.00, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 177.78% upside from the last price of $2.88.

This chart shows the closing price for MDXH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in MDxHealth. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/31/2023TD CowenInitiated CoverageOutperform$7.00Low
5/16/2023BTIG ResearchLower Target$8.00 ➝ $7.00Low
3/24/2023William BlairInitiated CoverageOutperformLow
3/9/2023BTIG ResearchLower Target$12.00 ➝ $8.00Low
3/6/2023Piper SandlerLower TargetOverweight$15.00 ➝ $10.00Low
8/26/2022BTIG ResearchBoost TargetBuy$13.00 ➝ $15.00Low
7/18/2022OppenheimerReiterated RatingOutperform$18.00Low
4/29/2022BTIG ResearchReiterated RatingBuy$13.00High
11/29/2021OppenheimerInitiated CoverageOutperform$18.00High
11/29/2021BTIG ResearchInitiated CoverageBuy$15.00High
11/29/2021Piper SandlerInitiated CoverageOverweight$15.00High
(Data available from 9/28/2018 forward)

News Sentiment Rating

-0.94 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/1/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
MDxHealth logo
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Read More

Today's Range

Now: $2.88
Low: $2.72
High: $2.90

50 Day Range

MA: $3.30
Low: $2.70
High: $3.82

52 Week Range

Now: $2.88
Low: $2.47
High: $8.51

Volume

14,352 shs

Average Volume

169,483 shs

Market Capitalization

$77.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of MDxHealth?

The following Wall Street analysts have issued reports on MDxHealth in the last twelve months: BTIG Research, Piper Sandler, TD Cowen, and William Blair.
View the latest analyst ratings for MDXH.

What is the current price target for MDxHealth?

3 Wall Street analysts have set twelve-month price targets for MDxHealth in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 184.7%. Piper Sandler has the highest price target set, predicting MDXH will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $7.00 for MDxHealth in the next year.
View the latest price targets for MDXH.

What is the current consensus analyst rating for MDxHealth?

MDxHealth currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDXH will outperform the market and that investors should add to their positions of MDxHealth.
View the latest ratings for MDXH.

What other companies compete with MDxHealth?

Other companies that are similar to MDxHealth include Genetron, Enzo Biochem, Personalis, DermTech and Exagen. Learn More about companies similar to MDxHealth.

How do I contact MDxHealth's investor relations team?

MDxHealth's physical mailing address is CAP Business Center, Herstal, Liege 4040. The company's listed phone number is 324-364-2070 and its investor relations email address is [email protected]. The official website for MDxHealth is mdxhealth.com. Learn More about contacing MDxHealth investor relations.